» Articles » PMID: 36928441

Non-alcoholic Fatty Liver Disease is Associated with Decreased Bone Mineral Density in Upper Egyptian Patients

Abstract

Nonalcoholic fatty liver disease (NAFLD) has been linked with a number of extra hepatic diseases and could be a potential risk factor of decreasing bone mineral density. To determine whether Upper Egyptian patients with NAFLD are at risk of developing osteoporosis. Cross sectional study was done on a total 100 individuals; 50 patients diagnosed with NAFLD (based on ultrasound imaging) crossed-matched with 50 individuals without NAFLD based on age, sex and body mass index. Bone mineral density, serum calcium and phosphorus levels, serum parathyroid hormone, serum vitamin D and fasting insulin level were assessed. Osteoporosis was prevalent in NAFLD patients versus to controls (19/50 vs. 0/50; P < 0.001). There was significant decrease in bone mineral density in NAFLD patients than controls (- 2.29 ± 0.4 vs. - 1.53 ± 0.1; P < 0.001). There was a statistical significance decrease in serum vitamin D and calcium levels in NAFLD patients than controls. Furthermore, vitamin D levels in the NAFLD group was a predictor for osteoporosis (OR 0.614; 95% CI 0.348-0.825). Patients with NAFLD tend to have a significant decrease in bone density, vitamin D, and serum calcium levels than controls.

Citing Articles

Nonlinear Association Between Serum Uric Acid and Femoral Neck Bone Mineral Density in Male Patients with Metabolic Dysfunction-Associated Fatty Liver Disease.

Tan J, Wang L, Li H, Wang H, Yang X Diabetes Metab Syndr Obes. 2025; 18():161-171.

PMID: 39845330 PMC: 11750728. DOI: 10.2147/DMSO.S492060.


Effects of Metabolic Dysfunction-Associated Steatotic Liver Disease on Bone Density and Fragility Fractures: Associations and Mechanisms.

Khanmohammadi S, Kuchay M J Obes Metab Syndr. 2024; 33(2):108-120.

PMID: 38740429 PMC: 11224928. DOI: 10.7570/jomes24004.


Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe.

Chondrogianni M, Kyrou I, Androutsakos T, Flessa C, Menenakos E, Chatha K Front Endocrinol (Lausanne). 2024; 15:1344376.

PMID: 38524631 PMC: 10957571. DOI: 10.3389/fendo.2024.1344376.

References
1.
Wade S, Strader C, Fitzpatrick L, Anthony M, OMalley C . Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos. 2014; 9:182. DOI: 10.1007/s11657-014-0182-3. View

2.
Wongdee K, Charoenphandhu N . Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms. World J Diabetes. 2011; 2(3):41-8. PMC: 3083906. DOI: 10.4239/wjd.v2.i3.41. View

3.
Lee S, Yun J, Kim S, Seo Y, Min H, Chung E . Association between bone mineral density and nonalcoholic fatty liver disease in Korean adults. J Endocrinol Invest. 2016; 39(11):1329-1336. DOI: 10.1007/s40618-016-0528-3. View

4.
Kaya M, Isik D, Bestas R, Evliyaoglu O, Akpolat V, Buyukbayram H . Increased bone mineral density in patients with non-alcoholic steatohepatitis. World J Hepatol. 2013; 5(11):627-34. PMC: 3847946. DOI: 10.4254/wjh.v5.i11.627. View

5.
Yang K, Hung H, Lu C, Chang H, Lee L, Huang K . Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance. Sci Rep. 2016; 6:27034. PMC: 4887873. DOI: 10.1038/srep27034. View